
2030 年までのヨーロッパのヒトワクチンアジュバント市場予測 - 地域分析 - タイプ別 (粒子状アジュバント、エマルジョンアジュバント、複合アジュバントなど)、用途別 (インフルエンザ、肝炎、ヒトパピローマウイルス (HPV) など)、エンドユーザー別 (製薬およびバイオテクノロジー企業、CMO および CRO など)
No. of Pages: 113 | Report Code: BMIRE00030406 | Category: Life Sciences
No. of Pages: 113 | Report Code: BMIRE00030406 | Category: Life Sciences
1. Creative Biolabs Inc
2. Croda International Plc
3. CSL Ltd
4. Dynavax Technologies Corp
5. Novartis AG
6. Novavax Inc
7. Phibro Animal Health Corp
8. Seppic SA
9. SPI Pharma Inc
The Europe Human Vaccine Adjuvants Market is valued at US$ 472.33 Million in 2022, it is projected to reach US$ 1,338.00 Million by 2030.
As per our report Europe Human Vaccine Adjuvants Market, the market size is valued at US$ 472.33 Million in 2022, projecting it to reach US$ 1,338.00 Million by 2030. This translates to a CAGR of approximately 13.9% during the forecast period.
The Europe Human Vaccine Adjuvants Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Human Vaccine Adjuvants Market report:
The Europe Human Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Human Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Human Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.